Brokerages forecast that Achaogen Inc (NASDAQ:AKAO) will report $3.86 million in sales for the current fiscal quarter, Zacks reports. Six analysts have issued estimates for Achaogen’s earnings, with the highest sales estimate coming in at $6.30 million and the lowest estimate coming in at $2.23 million. Achaogen reported sales of $1.87 million in the same quarter last year, which would suggest a positive year over year growth rate of 106.4%. The business is expected to issue its next quarterly earnings report on Tuesday, February 26th.
According to Zacks, analysts expect that Achaogen will report full-year sales of $10.48 million for the current year, with estimates ranging from $8.93 million to $13.00 million. For the next financial year, analysts anticipate that the firm will post sales of $29.77 million, with estimates ranging from $11.15 million to $55.50 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Achaogen.
Achaogen (NASDAQ:AKAO) last released its quarterly earnings results on Thursday, November 8th. The biopharmaceutical company reported ($0.88) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.96) by $0.08. Achaogen had a negative return on equity of 214.74% and a negative net margin of 2,045.86%. The firm had revenue of $2.00 million for the quarter, compared to the consensus estimate of $3.80 million.
Shares of AKAO traded down $0.04 during midday trading on Friday, hitting $1.39. The stock had a trading volume of 435,400 shares, compared to its average volume of 2,154,837. Achaogen has a twelve month low of $1.14 and a twelve month high of $15.00. The company has a market capitalization of $62.95 million, a price-to-earnings ratio of -0.44 and a beta of 0.83. The company has a debt-to-equity ratio of 1.00, a current ratio of 2.54 and a quick ratio of 2.52.
In related news, major shareholder Robert W. Duggan bought 743,348 shares of the stock in a transaction that occurred on Tuesday, December 11th. The shares were acquired at an average price of $1.62 per share, with a total value of $1,204,223.76. Following the completion of the transaction, the insider now owns 8,880,461 shares in the company, valued at $14,386,346.82. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Robert W. Duggan bought 80,175 shares of the stock in a transaction that occurred on Friday, November 23rd. The stock was bought at an average cost of $1.89 per share, for a total transaction of $151,530.75. Following the transaction, the insider now owns 8,343,945 shares of the company’s stock, valued at approximately $15,770,056.05. The disclosure for this purchase can be found here. In the last ninety days, insiders purchased 1,008,362 shares of company stock worth $1,677,078. 7.80% of the stock is owned by company insiders.
Several large investors have recently added to or reduced their stakes in AKAO. JPMorgan Chase & Co. increased its position in shares of Achaogen by 2,745.0% in the third quarter. JPMorgan Chase & Co. now owns 294,768 shares of the biopharmaceutical company’s stock valued at $1,176,000 after acquiring an additional 284,407 shares during the last quarter. AXA increased its position in Achaogen by 31.4% during the third quarter. AXA now owns 903,425 shares of the biopharmaceutical company’s stock worth $3,605,000 after buying an additional 215,989 shares during the last quarter. SG Americas Securities LLC acquired a new position in Achaogen during the third quarter worth approximately $823,000. Bank of America Corp DE increased its position in Achaogen by 274.7% during the second quarter. Bank of America Corp DE now owns 198,204 shares of the biopharmaceutical company’s stock worth $1,717,000 after buying an additional 145,305 shares during the last quarter. Finally, Granahan Investment Management Inc. MA acquired a new position in Achaogen during the second quarter worth approximately $1,220,000. 45.59% of the stock is currently owned by institutional investors and hedge funds.
Achaogen, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of antibacterial treatments for multi-drug resistant (MDR) gram-negative infections. It offers Plazomicin to treat bacterial illness, such as complicated urinary tract infection, blood stream infections, and other infections due to MDR Enterobacteriaceae.
Recommended Story: What is the Ex-Dividend Date in Investing?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Achaogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen and related companies with MarketBeat.com's FREE daily email newsletter.